Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 09:05:25 02/05/2024 pm IST 5-day change 1st Jan Change
328.6 GBX -0.73% Intraday chart for Haleon plc -1.26% +2.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Deutsche Bank likes TP ICAP but says sell CMC AN
HALEON : Q1 profitability beat; guidance unchanged Alphavalue
FTSE 100 down ahead of US interest rate decision AN
Haleon Q1 Revenue Declines 2.2% Year on Year MT
Haleon plc Announces Directorate Change CI
Haleon plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : Haleon plc, Q1 2024 Sales/ Trading Statement Call, May 01, 2024
Haleon backs guidance as profit edges up in first quarter AN
FTSE 100 shakes off New York slump before Fed AN
Sensodyne-maker Haleon posts tepid sales as demand for some products cools off RE
Haleon's first-quarter revenue misses expectations RE
GSK ups outlook; Next first-quarter beats forecast AN
Haleon Pretax Profit Rises Despite Revenue Drop DJ
Haleon Posts Higher Q1 Attributable Profit; Revenue Down MT
Sensodyne maker Haleon to shut UK factory with loss of 435 jobs AN
Haleon to Cut 435 Jobs, Shut U.K. Production Site DJ
Sensodyne-maker Haleon to close UK manufacturing site, with over 400 jobs hit RE
Moody’s Affirms Haleon’s Ratings on Strong Operating Performance MT
Haleon: a new CFO at the end of October CF
Haleon appoints Tate & Lyle's finance chief as CFO from November AN
Haleon Taps Tate & Lyle Finance Chief Dawn Allen as CFO DJ
British Healthcare Company Haleon Names Tate & Lyle CFO as New Finance Chief MT
Haleon names Dawn Allen as CFO RE
Haleon plc Announces Management Changes CI
Haleon plc Announces Chief Financial Officer Changes CI
Chart Haleon plc
More charts
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.31 GBP
Average target price
3.617 GBP
Spread / Average Target
+9.27%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. News Haleon plc
  5. Haleon to Weigh Large Potential Deals to Expand Its Brand Portfolio